Publications by authors named "Martin Struijs"
This first-in-human study (NCT03032588), conducted in Belgium, evaluated a new inactivated poliovirus vaccines (IPV) candidate based on Sabin poliovirus strains grown on the high-yield PER.C6® cell line. Healthy adults (N = 32) were randomized (1:1) to receive a single dose of PER.
View Article and Find Full Text PDFArticle Synopsis
- This report analyzes the long-term effects of using plerixafor with G-CSF for stem cell mobilization in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM).
- The study included 167 NHL patients and 163 MM patients, comparing outcomes of those treated with plerixafor versus a placebo over a 5-year period.
- Results showed no significant differences in overall survival (OS) or progression-free survival (PFS) between the treatment groups, indicating that adding plerixafor did not improve survival outcomes for either NHL or MM patients.